Skip to main content

Jim Cramer Says Emergent Bio Is a Buy on Vaccine News

Publish date:
Video Rating:
Video Duration:

Emergent and Johnson & Johnson have a manufacturing agreement for JNJ's  (JNJ) - Get Johnson & Johnson Report COVID-19 vaccine. 

The vaccine, which received an emergency use authorization from the Food & Drug Administration over the weekend, is now the third vaccine to start being distributed in the United States.

Per a press release from July 2020, "Under the agreement, Emergent will begin providing large-scale drug substance manufacturing for Johnson & Johnson’s adenovirus-based COVID-19 vaccine in 2021, upon successful completion of the activities under the previously executed Technology Transfer Agreement. For the subsequent years beginning 2023, Emergent will provide a flexible capacity deployment model to support additional drug substance batches annually."

Recap TheStreet Live: Everything Jim Cramer Is Watching in the Markets Monday

Related Videos